Warning – Your Medications!


Warning – Your Medications!



Did You Know This About Your Medications?



That’s right… your Doctor may have prescribed you any
number of the following medications – for your UC, Crohn’s, IBD:


Are you on any of these?

5ASA – Mesalamine Oral Meds:
Pentasa, Asacol, Salofalk, Lialda, Apriso, Azulfidine
+ many generics available outside the US

➢ Olsalazine (Dipentum®) – diazo bond of two 5-ASAs, colonic release
➢ Pentasa® – ethylcellulose/5-ASA beads, small bowel and colonic release
➢ Asacol® – Eudragit-S coating that releases at pH7, ileocolonic release
➢ Colazal® – diazo bond to inert polymer, colonic release
➢ Lialda® – Eudragit-S coating of metallomatrix 5-ASA, ileocolonic release
➢ Apriso® – Eudragit-L (pH6) coating of 5-ASA-polymer coated beads, small bowel and colonic release
➢ Asacol-HD® – Eudragit-S and Eudragit-L coating, ileocolonic release


5ASAs or Mesalamines have
potentially dangerous side
effects, both short term and
long term.



More importantly, some people
are allergic or intolerant of them,
and it can actually made your
symptoms of IBD, UC, or Crohn’s
even WORSE!



If you’re intolerant, you could be
experiencing  terrible headaches,
terrible stomach pains, and liquid
diarrhea all the time??


Could you imagine?



That’s what happened to me.
I was in pain and on the toilet
all the time, but my Gastro decided
to switch me to another 5ASA, and
that didn’t help the problems,
as I was still suffering so much…
and he NEVER told me it could
be an allergic or intolerant reaction
to the actual medication.  After
3 months, I couldn’t take it anymore
and I decided to stop all the medication
all together.


*Please note:
Don’t Stop Your Medication.
If you think you may have an
intolerance issue, please
don’t wait, speak to your doctor or
pharmacist right away.



And guess what, all those
symptoms – terrible headache,
stomach pains, constant liquid
and bloody diarrhea – went away!



Yes, I still had UC, BUT I found
a better way to treat it, and as result,
have been in remission since. If you’re
please contact me.



Since starting my website, I have
heard from many who have
gone through the same
unfortunate experience of thinking

their UC or Crohn’s had gotten
much worse, when in fact it was
an intolerance to the 5ASA’s.




Common allergic reactions:

  1. increased abdominal pain,
  2. bloating,
  3. gas,
  4. headaches,
  5. terrible watery diarrhea,
  6. rashes,
  7. cardiac like symptoms,
  8. and even bleeding.



Here’s the Problem, which your
doctor probably failed to inform
you of:

YOU can take the 5ASAs or
mesalamines for a while and
then develop an intolerance
to them (symptoms noted above)
and mistakenly think their IBD has
taken a turn for the worst
and they’ve started a flare,
when it was just an intolerance
to the mesalamines.


Some common side effects can be: 

  • hair loss,
  • decreased libido,
  • joint pains
  • liver damage
  • kidney damage
  • kidney failure ( can occur, but is not common)
  • liver failure (can occur, but is not common)

From RX.com, on Pentasa:

“…Infrequently, mesalamine can worsen ulcerative colitis.
Tell your doctor right away if your symptoms worsen
after starting this medication (such as increased abdominal pain/cramping, bloody diarrhea, fever).

Tell your doctor right away if you have any serious
side effects, including: change in the amount of urine,
dark urine, persistent nausea/vomiting, severe stomach/abdominal pain, yellowing eyes/skin,
chest pain, shortness of breath.

A very serious allergic reaction to this drug is rare.
However, get medical help right away if you notice
any symptoms of a serious allergic reaction,
including: rash, itching/swelling (especially
of the face/tongue/throat), severe dizziness,
trouble breathing.

This is not a complete list of possible side effects.
If you notice other effects not listed above, contact
your doctor or pharmacist…”

Click here to read it.



From Rx.com, on Lialda:

Renal Impairment

Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products such as LIALDA that contain mesalamine or are converted to mesalamine.

It is recommended that patients have an evaluation of renal function prior to initiation of LIALDA therapy and periodically while on therapy. Exercise caution when using LIALDA in patients with known renal dysfunction or a history of renal disease.

In animal studies, the kidney was the principal organ for toxicity. [See DRUG INTERACTIONS and Nonclinical Toxicology]

Mesalamine-Induced Acute Intolerance Syndrome

Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of ulcerative colitis. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain and bloody diarrhea, and sometimes fever, headache, and rash. Observe patients closely for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with LIALDA.

Hypersensitivity Reactions

Some patients who have experienced a hypersensitivity reaction to sulfasalazine may have a similar reaction to LIALDA tablets or to other compounds that contain or are converted to mesalamine.

Mesalamine-induced cardiac hypersensitivity reactions (myocarditis andpericarditis) have been reported with LIALDA and other mesalamine medications. Caution should be taken in prescribing this medicine to patients with conditions predisposing them to the development of myocarditis or pericarditis.

Hepatic Impairment

There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine. Caution should be exercised when administering LIALDA to patients with liver disease.

Upper GI Tract Obstruction

Pyloric stenosis or other organic or functional obstruction in the uppergastrointestinal tract may cause prolonged gastric retention of LIALDA which would delay mesalamine release in the colon.

Interference With Laboratory Tests

Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and mesalamine’s main metabolite, N-acetylaminosalicylic acid (N-Ac-5-ASA). An alternative, selective assay for normetanephrine should be considered.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility


In a 104-week dietary carcinogenicity study in CD-1 mice, mesalamine at doses up to 2500 mg/kg/day was not tumorigenic. This dose is 2.2 times the maximum recommended human dose (based on a body surface areacomparison) of LIALDA. Furthermore, in a 104-week dietary carcinogenicity study in Wistar rats, mesalamine up to a dose of 800 mg/kg/day was not tumorigenic. This dose is 1.4 times the recommended human dose (based on a body surface area comparison) of LIALDA.


No evidence of mutagenicity was observed in an in vitro Ames test or an in vivo mouse micronucleus test.

Impairment of Fertility

No effects on fertility or reproductive performance were observed in male or female rats at oral doses of mesalamine up to 400 mg/kg/day (0.7 times the maximum recommended human dose based on a body surface area comparison).

Use In Specific Populations


Pregnancy Category B

Reproduction studies with mesalamine have been performed in rats at doses up to 1000 mg/kg/day (1.8 times the maximum recommended human dose based on a body surface area comparison) and rabbits at doses up to 800 mg/kg/day (2.9 times the maximum recommended human dose based on a body surface area comparison) and have revealed no evidence of impaired fertility or harm to the fetus due to mesalamine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Mesalamine is known to cross the placental barrier.

Nursing Mothers

Low concentrations of mesalamine and higher concentrations of its N-acetyl metabolite have been detected in human breast milk. The clinical significance of this has not been determined and there is limited experience of nursing women using mesalamine. Caution should be exercised if LIALDA is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of LIALDA in pediatric patients have not been established.

Geriatric Use

Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of blood dyscrasias, i.e., neutropeniaand pancytopenia in patients who were 65 years or older who were taking mesalamine-containing products such as LIALDA. Caution should be taken to closely monitor blood cell counts during mesalamine therapy.

Clinical trials of LIALDA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic exposures are increased in elderly subjects. [see CLINICAL PHARMACOLOGY]. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concurrent disease or other drug therapy in elderly patients.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 10/31/2014



These precautions and warnings are not
limited to the oral mesalamines or 5ASA’s,
they also include 5ASA enemas,
please see the following, from Drugs.com:

“Possible side effects of mesalamine enema:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Flu-like symptoms; gas; hemorrhoids; mild headache; mild stomach discomfort or pain; nausea; rectal pain.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); back, leg, or joint pain; blood in the urine; bloody or coffee ground-like vomit; change in the amount of urine; chest pain; dark, bloody, or tarry stools; fever, chills, or persistent sore throat; hair loss; severe or persistent headache; shortness of breath; sudden or severe stomach pain or cramping; symptoms of liver problems (eg, dark urine; pale stools; severe or persistent nausea, loss of appetite, or stomach pain; unusual tiredness; yellowing of the skin or eyes); unusual bruising or bleeding.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.”

Click here to read it


So What to do?

Is there an effective alternative to the 5ASA’s or Mesalamines?


Yes, You can read about it by clicking here



Comments are closed.